文献速递浆细胞疾病

使用血清游离轻链检测诊断和监测仅轻链型及寡分泌型骨髓瘤

Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.
PubMed 文献 · Br J Haematol · 2017-06-01

研究纳入5573例新诊断骨髓瘤患者,其中576例为仅轻链型(LCO)、60例为非分泌型(NS),用Freelite®和Seralite®检测血清游离轻链(sFLC)。两种方法均能灵敏诊断和监测LCO/寡分泌型骨髓瘤,sFLC缓解与更好生存相关,Seralite®快速检测可加速筛查和监测。

要点

  • Freelite® sFLC≥100 mg/l用于评估缓解的阈值得到确认,等效的Seralite® dFLC>20 mg/l也被确定。
  • 按任一sFLC方法达到至少非常好的部分缓解与更好的患者生存相关。
  • Freelite® sFLC升高>200 mg/l与Seralite® dFLC升高>30 mg/l识别复发具有100%一致性。

核心结论

  • Freelite®和Seralite®均能灵敏诊断和监测仅轻链型/寡分泌型骨髓瘤。
  • Seralite®快速检测可加速FLC筛查和监测。
  • sFLC评估的缓解对生存具有预后价值,体现了常规sFLC检测的临床价值。

研究设计与样本

  • 研究纳入5573例新诊断骨髓瘤患者,通过血液和尿液分析识别出576例仅轻链型(LCO)和60例非分泌型(NS)病例。
  • 在诊断时、最大缓解时和复发时,用Freelite®和Seralite®检测血清。

主要发现

  • 20%的LCO患者尿液FLC水平低于推荐用于评估缓解的阈值,但其中>97%有足够的sFLC水平(寡分泌型)。
  • 按两种方法,≥38%的NS患者有可测量疾病(寡分泌型)。
  • Freelite®在所有时间点观察到的sFLC水平更高,但在诊断时和治疗缓解中观察到良好的临床一致性。
  • 按任一sFLC方法达到至少非常好的部分缓解与更好的患者生存相关。
  • 使用Freelite® sFLC升高>200 mg/l识别复发,与相应的Seralite® dFLC升高>30 mg/l发现100%一致性。

关键数值与推荐

  • 推荐用于评估缓解的Freelite® sFLC≥100 mg/l得到确认,等效的Seralite® FLC差值(dFLC)>20 mg/l被确定。
  • Freelite® sFLC升高>200 mg/l用于识别复发,与Seralite® dFLC升高>30 mg/l具有100%一致性。

临床怎么用

  • Freelite®和Seralite®均可用于仅轻链型/寡分泌型骨髓瘤的诊断和监测。
  • Seralite®快速检测可加速FLC筛查和监测。
  • 常规sFLC检测具有临床价值,sFLC评估的缓解对生存具有预后意义。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study aims to guide the integration of serum free light chain (sFLC) tests into clinical practice, including a new rapid test (Seralite® ). Blood and urine analysis from 5573 newly diagnosed myeloma patients identified 576 light chain only (LCO) and 60 non-secretory (NS) cases. Serum was tested by Freelite® and Seralite® at diagnosis, maximum response and relapse. 20% of LCO patients had urine FLC levels below that recommended for measuring response but >97% of these had adequate sFLC levels (oligosecretory). The recommended Freelite® sFLC ≥100 mg/l for measuring response was confirmed and the equivalent Seralite® FLC difference (dFLC) >20 mg/l identified. By both methods, ≥38% of NS patients had measurable disease (oligosecretory). Higher sFLC levels were observed on Freelite® at all time points. However, good clinical concordance was observed at diagnosis and in response to therapy. Achieving at least a very good partial response according to either sFLC method was associated with better patient survival. Relapse was identified using a Freelite® sFLC increase >200 mg/l and found 100% concordance with a corresponding Seralite® dFLC increase >30 mg/l. Both Freelite® and Seralite® sensitively diagnose and monitor LCO/oligosecretory myeloma. Rapid testing by Seralite® could fast-track FLC screening and monitoring. Response by sFLC assessment was prognostic for survival and demonstrates the clinical value of routine sFLC testing.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Heaney JLJ, Campbell JP, Griffin AE, et al. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Br J Haematol. 2017. PMID: 28573706. doi:10.1111/bjh.14753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。